TY - JOUR
T1 - Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors
T2 - Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study
AU - Leerink, Jan M.
AU - Feijen, E. Lieke A.M.
AU - van der Pal, Helena J.H.
AU - Kok, Wouter E.M.
AU - Mavinkurve-Groothuis, Annelies M.C.
AU - Kapusta, Livia
AU - Pinto, Yigal M.
AU - Maas, Angela H.E.M.
AU - Bellersen, Louise
AU - Teske, Arco J.
AU - Ronckers, Cécile M.
AU - Louwerens, Marloes
AU - van Dalen, Elvira C.
AU - van Dulmen-den Broeder, Eline
AU - Batenburg, Lilian
AU - van der Heiden-van der Loo, Margriet
AU - van den Heuvel-Eibrink, Marry M.
AU - van Leeuwen, Flora E.
AU - de Vries, Andrica C.H.
AU - Weijers, Gert
AU - de Korte, Chris L.
AU - Loonen, Jacqueline J.
AU - Neggers, Sebastian J.C.M.M.
AU - Versluys, A. B.Birgitta
AU - Tissing, Wim J.E.
AU - Kremer, Leontien C.M.
N1 - Funding Information:
We thank Bep Verkerk and Martine Raphael for their contributions at the LATER registry and coordinating office as well as all data managers in the seven participating centers and Aslihan Mantici for obtaining the data for this study. Furthermore, we thank Margreet Veening for her contributions as a late effects outpatient clinic physician and Lideke van der Steeg for her contribution as a LATER board member. We would also like to thank all cancer survivors and siblings participating in the study and the VOKK and VOX for their contribution to the LATER CARD study. Individual participant data, after de-identification, may be shared with investigators who would like to collaborate after the main analyses of the LATER CARD study are finished. Applications of intent can be sent to [email protected] and will be reviewed by the LATER study group. None declared.
Publisher Copyright:
© 2019 The Authors
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-term childhood cancer survivors (CCS). We hypothesize that assessment of more sensitive echo- and electrocardiographic measurements, and/or biomarkers will allow for improved recognition of patients with cardiac dysfunction before heart failure develops, and may also identify patients at lower risk for heart failure. Objective: To describe the methodology of the Dutch LATER cardiology study (LATER CARD). Methods: The LATER CARD study is a cross-sectional study in long-term CCS treated with (potentially) cardiotoxic cancer therapies and sibling controls. We will evaluate 1) the prevalence and associated (treatment related) risk factors of subclinical cardiac dysfunction in CCS compared to sibling controls and 2) the diagnostic value of echocardiography including myocardial strain and diastolic function parameters, blood biomarkers for cardiomyocyte apoptosis, oxidative stress, cardiac remodeling and inflammation and ECG or combinations of them in the surveillance for cancer therapy-related cardiac dysfunction. From 2017 to 2020 we expect to include 1900 CCS and 500 siblings. Conclusions: The LATER CARD study will provide knowledge on different surveillance modalities for detection of cardiac dysfunction in long-term CCS at risk for heart failure. The results of the study will enable us to improve long-term follow-up surveillance guidelines for CCS at risk for heart failure.
AB - Background: Cancer therapy-related cardiac dysfunction and heart failure are major problems in long-term childhood cancer survivors (CCS). We hypothesize that assessment of more sensitive echo- and electrocardiographic measurements, and/or biomarkers will allow for improved recognition of patients with cardiac dysfunction before heart failure develops, and may also identify patients at lower risk for heart failure. Objective: To describe the methodology of the Dutch LATER cardiology study (LATER CARD). Methods: The LATER CARD study is a cross-sectional study in long-term CCS treated with (potentially) cardiotoxic cancer therapies and sibling controls. We will evaluate 1) the prevalence and associated (treatment related) risk factors of subclinical cardiac dysfunction in CCS compared to sibling controls and 2) the diagnostic value of echocardiography including myocardial strain and diastolic function parameters, blood biomarkers for cardiomyocyte apoptosis, oxidative stress, cardiac remodeling and inflammation and ECG or combinations of them in the surveillance for cancer therapy-related cardiac dysfunction. From 2017 to 2020 we expect to include 1900 CCS and 500 siblings. Conclusions: The LATER CARD study will provide knowledge on different surveillance modalities for detection of cardiac dysfunction in long-term CCS at risk for heart failure. The results of the study will enable us to improve long-term follow-up surveillance guidelines for CCS at risk for heart failure.
UR - http://www.scopus.com/inward/record.url?scp=85074749741&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2019.10.010
DO - 10.1016/j.ahj.2019.10.010
M3 - Article
C2 - 31733449
AN - SCOPUS:85074749741
SN - 0002-8703
VL - 219
SP - 89
EP - 98
JO - American Heart Journal
JF - American Heart Journal
ER -